DYNLT3

Across TCGA pan-cancer cohorts, DYNLT3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated DYNLT3 data layer compared with 22 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher DYNLT3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated DYNLT3 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, PDAC, and HNSC are the cancer types where DYNLT3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	IV	0.794	0.137	.024	7	view →
PDAC	OS	Median	All	0.596	0.410	.026	7	view →
HNSC	OS	Median	II,III,IV	0.933	0.992	.024	4	view →
UCEC	DFS	Quartile	All	0.869	0.644	.033	4	view →
LUAD	DFS	Quartile	II,III,IV	0.745	0.908	.024	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

DYNLT3–CCRCC (DFS)

Open the CCRCC breakdown →